Navigation Links
Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers
Date:4/17/2008

Tepha Corporate Partners, Aesculap and Tornier, Conduct Clinical

Evaluations of TephaFLEX(R) Suture Products

LEXINGTON, Mass., April 17 /PRNewswire/ -- Tepha, Inc., a developer of medical devices derived from a new class of polymers, announced today that two of its corporate partners, Aesculap and Tornier, are conducting initial clinical evaluations of the Company's new TephaFLEX(R) suture products. These clinical evaluations, conducted in both the United States and Europe, represent the first human usage of medical devices derived from Tepha's new class of resorbable polymers called polyhydroxyalkanoates ("PHA's"). The Tepha PHA polymer family is a product of the Company's patented recombinant DNA technology which allows the engineering of resorbable medical devices with mechanical and biologic properties that are matched to specific tissue repair and replacement applications. TephaFLEX(R) monofilament suture is up to 30% stronger, more flexible, and has longer strength retention than currently marketed resorbable sutures.

Dr. Simon Williams, President and CEO of Tepha, commented, "The first human usage of a medical device based on our proprietary polymer technology is an important milestone in Tepha's history. We are grateful for the support of such capable and committed partners as Aesculap and Tornier, and we look forward to these collaborations progressing to the successful commercialization of TephaFLEX(R) suture products."

Aesculap AG, a Tepha corporate partner since 2004, currently is conducting a European trial evaluating suture products based on TephaFLEX(R) fiber in 150 patients undergoing abdominal wall repair procedures. The results of this trial will be submitted to European regulatory authorities to support Aesculap's application for CE Mark approval. Based in Germany, Aesculap is a division of B. Braun Melsungen AG, focused on products for core processes in operative medicine. Aesculap's product range i
'/>"/>

SOURCE Tepha, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/6/2009)... Successful Results from prior U.S., U.K. and Chin...Vital Therapies, Inc. (VTI), a development stage c...tient enrollment has begun for a randomized, contr...ill study the Extracorporeal Liver Assist Device (... Failure (ALF) under three protocols. The study is...
(Date:1/6/2009).... 6 In recent controlled studies c...mphis , scientists found that the patented ingredi...nd only proven ingredient to increase levels of ni...ood nitrate/nitrate (NOx) in human subjects. , ,...n increase in blood flow to the skeletal muscles. ...
(Date:1/6/2009)...n. 6 Sequella, Inc., a ...n diseases of epidemic potential, announced today ...ent of tuberculosis (TB), was the first drug appro...gram contract to Dynport Vaccine Company LLC and Q...he National Institute of Allergy and Infectious Di...
(Date:1/6/2009)...J., Jan. 6 Pacira Pharmaceuticals,...pany, announced today that enrollment,has been co...evaluate the,safety and efficacy of a single intr...ivacaine) for prolonged postoperative analgesia. ,...my and in total knee,arthroplasty (TKA) are expec...
Breaking Medicine Technology:ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 3US Testing Proves Glyc'n Go(TM) Increases NO in the Blood Stream 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment 2Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment 3 C O R R E C T I O N from Source Resverlogix Corp 5055 1 C O R R E C T I O N from Source Resverlogix Corp 5055 2Cold Spring Harbor Protocols features classic approaches for analyzing chromosomes 3151 1ACC Observes National Drinking Water Week 18231 1ACC Observes National Drinking Water Week 18231 2Advanced Life Sciences to Host 2008 First Quarter Financial Results Conference Call and Webcast 5052 1Advanced Life Sciences to Host 2008 First Quarter Financial Results Conference Call and Webcast 5052 2Advanced Life Sciences to Host 2008 First Quarter Financial Results Conference Call and Webcast 5052 3
(Date:1/8/2009)...sessment for heart risk may not be accurate in som...News) -- Two studies, from the United States and t... the long-established Framingham Risk Score in pre..., The Framingham score, based on findings of a de...allows doctors to assess risk on the basis of seve...
(Date:1/8/2009)...PRNewswire/ -- A study released this week showing ...rom multiple chronic diseases shines a much-needed...re system to one that focuses on primary and secon...cine, the leader in disease prevention. , , (...06/NETU129LOGO ) , , The study, conducted by ...
(Date:1/8/2009)... sitting on the surface of cancer cells are keys t...reating and stopping the spread of certain types o...e, breast, ovarian and lung, among others. Armed ...teway for Cancer Research, an Illinois-based phila...o, M.D., Ph.D., and her co-workers at the Moores C...
(Date:1/8/2009)...ude study could shape new treatments for secondary...re-USNewswire/ -- Scientists at St. Jude Children,...tive treatment for bacterial pneumonia following i...cin and azithromycin, which kill bacteria by inhib...than a standard first-line treatment with the "bet...
Breaking Medicine News(10 mins):Health News:Studies Challenge Framingham Risk Score 2Health News:Studies Challenge Framingham Risk Score 3Health News:U.S. Preventive Medicine: Chronic Disease Study Demonstrates Need for Focus on Primary and Secondary Prevention 2Health News:Novel prostate cancer vaccine taking aim at cancer cell 'sweet spot' 2Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 2Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 3
...! New research released on Monday suggests that a ... healthy and prolongs life. These findings stem fr...e in nuns. "It's been known for years that patholo...ssion or hostility can lead to illness," said Davi...
... during clinical trials, may be the in thing in AI...e HIV from circulating blood, has been developed a... mark the beginning of the end of HIV’s vicious gr...rs at Aethlon Medical, a biotechnology firm in La ...
..., may opt for mastectomy over breast-conserving lu... gene mutation, researchers said California on Mon...sed by an inherited genetic susceptibility. The ma...utations or alterations in two genes, BRCA1 and BR...
... AIDS therapy, complimentary and alternative medic...e patients, according to a new study. Among 191 HI... complementary and alternative therapies, 67% said...t to control their HIV infection and 40% reported ...
Other Medicine News:
... modular external fixation system designed to acco...needs. Originally marketed in Europe under the Fix...y of clinical use in the global healthcare marketp...rov technique begun in Russia over 50 years ago, R...
...N AVIA tonometer is an easy-to-use, hand-held inst...trongly with Goldmann tonometry. TONO-PEN AVIA has...tronic measurement technology that enables operato... minimal training. TONO-PEN AVIA is powered by a l...
The QuickLink™ Delivery System is a cartridge based device designed to assemble brachytherapy seeds, spacers and SourceLink Connectors into seed trains of variable lengths and with variable seed
...ollection benefits from innovative research in mat...ectors such as the aerospace and automotive indust... and the footwear and textile industry. , ,This kn...Carrera sunglasses collection to create unique and...
Medicine Products: